Ally Bridge Group led a $265m Series B round in Sonoma Biotherapeutics.

Ally Bridge Group, a healthcare-focused investment group, led a $265m Series B round in Sonoma Biotherapeutics, a company that develops adoptive therapies cell for autoimmune. Additional investors included ArrowMark, Avidity Partners, Casdin Capital, Deep Track Capital, Fidelity Management & Research Company, Frazier Healthcare Partners, GV, Janus Henderson Investors, Mirae Asset, NS Investment, Osage University Partners, Piper Heartland Healthcare Capital, Vertex Ventures, 8VC, ARCH Venture Partners, Alexandria Venture Investments, the JDRF T1D Fund, LifeForce Capital, Lilly Asia Ventures and Octagon Capital. “We’re proud to lead Sonoma Bio’s Series B financing and support their game-changing efforts to fundamentally change the treatment of autoimmune diseases. Sonoma Bio, which creates a new therapeutic paradigm, has assembled a leading world-class team who are pioneering technology to unlock this novel cell therapy approach for autoimmune and inflammatory diseases," Frank Yu, Ally Bridge Group Founder and CEO.